Related Experiment Videos
Cinnamamide analogs as inhibitors of protein tyrosine kinases
F Buzzetti1, M G Brasca, A Crugnola
1Ricerca e Sviluppo, Farmitalia Carlo Erba Srl, Milano, Italy.
Abstract:
Protein tyrosine kinases (PTK) are important signal transducing enzymes involved in the modulation of normal cellular growth and differentiation and have been associated with the etiology of various human cancers. The development of properly designed inhibitors, which block their function by interfering with the substrate binding, may therefore offer an unique target for selective anticancer chemotherapy. Here we describe synthesis and biochemical testing of a novel series of non-peptide PTK inhibitors which have as characteristic active pharmacophore the cinnamamide moiety. For testing we used an exogenous substrate kinase assay based on the phosphorylation of (Val5)-angiotensin II with radiolabelled ATP by the catalytic domain of the PTK encoded by the v-abl oncogene (p45 v-abl). The most potent compounds were found in the class of 3-arylidene-2-oxindoles (II) with IC50 values in the 1 microM range. Among these the 2-tetralylmethylene-, 4-quinolylmethylene-, 5-quinolylmethylene- and 3-indolylmethylene-2-oxindole compounds of formulae 16, 20, 21 and 24 respectively were selected for further investigation.
Insights
Novel non-peptide protein tyrosine kinase (PTK) inhibitors targeting cancer were synthesized. The most potent compounds, 3-arylidene-2-oxindoles, show promise for anticancer chemotherapy by blocking PTK function.
Area of Science:
- Medicinal Chemistry
- Biochemistry
- Oncology
Background:
- Protein tyrosine kinases (PTKs) are crucial signaling enzymes implicated in cell growth, differentiation, and cancer development.
- Targeting PTK activity offers a potential strategy for selective anticancer chemotherapy.
Purpose of the Study:
- To synthesize and biochemically evaluate a novel series of non-peptide PTK inhibitors.
- To identify potent PTK inhibitors with potential anticancer applications.
Main Methods:
- Synthesis of novel non-peptide compounds featuring a cinnamamide pharmacophore.
- Biochemical testing using an exogenous substrate kinase assay with radiolabeled ATP.
- Enzyme inhibition assays utilizing the catalytic domain of v-abl oncogene PTK (p45 v-abl).
Main Results:
- Identified 3-arylidene-2-oxindoles as a potent class of PTK inhibitors.
- Achieved IC50 values in the low micromolar range for the most effective compounds.
- Selected specific compounds (16, 20, 21, 24) for further investigation based on potency.
Conclusions:
- Novel non-peptide PTK inhibitors based on the cinnamamide moiety were successfully developed.
- 3-Arylidene-2-oxindole derivatives demonstrate significant inhibitory activity against PTKs.
- These findings support the potential of these compounds as leads for anticancer drug development.